Skip to content

To test the Efficacy of two anesthetic agents in patients with pulpal pain

Clinical Efficacy of Ropivacaine versus Lidocaine in patients with irreversible pulpitis - A Split Mouth Randomized Clinical Trial - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/12/060698
Enrollment
40
Registered
2023-12-22
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K040- Pulpitis

Interventions

Intervention1: 0.75% Ropivacaine: Ropivacaine hydrochloride is a long acting local amide anaesthetic. Ropivacaine has a biphasic vascular effect . In low concentration (0.063– 0.5%), it shows vasocons

Sponsors

DR Paluru Harika
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Healthy patients over 18 years old who had mandibular molars in need of root canal treatment in both the quadrants with irreversible pulpitis

Exclusion criteria

Exclusion criteria: Presence of systemic disorders Sensitivity to lidocaine with 1:80,000 epinephrine Presence of a periapical radiolucency Lactating and pregnant women Using any type of analgesic medication in the Preceding 12 hours before the treatment Teeth that were unsuitable for restoration,with full crowns Teeth associated with spontaneous severe pain that needed emergency treatment

Design outcomes

Primary

MeasureTime frame
To evaluate Anesthetic efficacy of Ropivacaine and Lidocaine using visual analog scale. Timepoint: 20 min after L.A During access cavity preparation ( entering in to dentin , pulp chamber) & instrument inserted in to the root canal.

Secondary

MeasureTime frame
To evaluate the success rate of lidocaine and Ropivacaine using cold test Timepoint: 15 mins before & after giving local anesthesia

Countries

India

Contacts

Public ContactDr Suneel kumar chinni

Narayana Dental College And Hospital

lavanyamds@gmail.com9346567413

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026